Delayed Nasdaq Helsinki 11:09:38 2024-04-19 am EDT 5-day change 1st Jan Change
2.73 EUR -0.73% Intraday chart for Bioretec Oy -5.54% +13.75%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bioretec Oy Announces Pekka Simula Not Available for Re-Election to Board of Directors CI
Finland's Bioretec Gets US Patent Allowance for Magnesium Alloy Composition MT
Bioretec Ltd. Receives a Patent by the U.S. Patent Office for its RemeOs Magnesium Alloy Composition CI
Bioretec Secures US FDA Breakthrough Device Designation for Spinal Interbody Cage Implant MT
Bioretec Has Been Granted FDA Breakthrough Device Designation Status for its RemeOs Spinal Interbody Cage CI
Bioretec Expects EU Regulatory Approval for Trauma Screw in Q2 MT
Bioretec's European Market Authorization for RemeOs Trauma Screw Proceeded to Expert Panel Evaluation CI
Bioretec to Initiate Search for New CEO MT
Bioretec Ltd Announces CEO Changes CI
Bioretec Estimates the Approval of the European Market Authorization for the Biodegradable RemeOs? Trauma Screw Will Move to the First Quarter of 2024 CI
Bioretec Secures Distribution Agreement for Trauma Screws in US Market MT
Bioretec Signs Distribution Deal for Launch of Orthopedic Product in US MT
Bioretec Ltd. Enters into the U.S. Distribution Agreement with Spartan Medical Inc. for the RemeOs Screws CI
Bioretec Wins R&D Grant from Business Finland for Developing Advanced Biodegradable Implants MT
Bioretec Ltd Unveils Its Revitalized Scientific Advisory Board CI
Bioretec Oy Appoints Esa Hallinen as Director of Operations and Member of the Management Team CI
Bioretec Ltd Acquires New CNC Machining Center to Increase Production Capacity of RemeOs Products at its Factory in Tampere, Finland CI
Bioretec Oy Approves Management Appointments CI
Bioretec Ltd Appoints Dr. Jeremy Dublon as Regulatory Advisor CI
Bioretec Ltd, Receives U.S. Market Authorization for Its RemeOs Trauma Screw from the U.S. Food and Drug Administration CI
Bioretec Wins US FDA Nod for Bioresorbable Orthopedic Implant MT
Bioretec Ltd Receives Market Authorization of the U.S. Food and Drug Administration for Its Pioneering Remeos Traversed with the Clinical Trial CI
Bioretec Submits Additional Data Requested By US FDA For Trauma Screw MT
Bioretec Ltd Submits Additional Information Requested by the FDA for US Registration of RemeOs Trauma Screws CI
Bioretec Ltd, Updates Estimate of U.S. registration of RemeOs™ Screws and Expects Approval in April 2023 CI
Chart Bioretec Oy
More charts
Bioretec Oy is a Finland-based medical device manufacturer company focusing on the development of strong, safe and reliable bioresorbable implants for pediatric and adult orthopedics. The Company operates as a developer, manufacturer and commercializer of innovative bioresorbable orthopedic implants and implant materials used for the treatment of bone and soft tissue injuries. Bioretec Oy’s existing Activa product portfolio consists of bioabsorbable biopolymer products that are alreadyavailable in the market for applications in pediatrics, trauma surgery as well as sports surgery. Bioretec Oy has one Germany-based subsidiary, BRI.Tech GmbH. The Company’s products are used all over the world.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.75 EUR
Average target price
3.75 EUR
Spread / Average Target
+36.36%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. BRETEC Stock
  4. News Bioretec Oy
  5. Bioretec Oy : Commences Trading On Nasdaq First North Growth Market Finland